OTTAWA, Ontario--(BUSINESS WIRE)-- Avivagen Inc. Inc. (TSXV:VIV) “Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, is pleased to announce its first purchase orders of OxC-beta™ Livestock in North America, and is finalizing sales agreements in Mexico with Industrias Melder , S.A. De C.V. (“Industrias Melder” or the “Company”).

“We are very excited to announce our first purchase orders of OxC-beta™ Livestock and Vivamune in Mexico, paving the way for continued distribution and acceptance of our technology in major feed markets worldwide,” said Kym Anthony, C.E.O. of Avivagen. “With annual feed sales of more than 36 million tonnes, compared with 18.2 million for The Philippines, 20.2 million for Thailand and 21.6 Million for Canada, Mexico represents a fast-growing and important market for OxC-beta™ Livestockⁱ. We are confident that, as in other markets around the world, the demand for OxC-beta™ Livestock in Mexico and throughout North America will rapidly expand.”

Established in 1949 and located in Guadalajara, Mexico, Industrias Melder is a feed miller that sells commercial feeds to dairy, poultry and swine producers. The Company has placed an order for purchase of 350 kgs of OxC-beta™ Livestock, as well as an order to purchase 1,000 bags of Vivamune to be sold through Super Pet, a chain of retail pet stores that the Company owns and operates.

In addition to these purchase orders, confirmatory testing of OxC-beta™ Livestock with different species is currently underway with Industrias Melder. These commitments followed Avivagen’s recent presentation of OxC-beta™ technology at a technical seminar series hosted by the Mexican Association of Food Producers (AMEPA) in Guadalajara. The AMEPA seminar series was attended by numerous association members consisting of feed and livestock producers.

About Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications. By unlocking an overlooked facet of β-carotene activity, a path has been opened to safely and economically support immune function, thereby promoting general health and performance in animals. Avivagen is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Taiwan, New Zealand, Thailand, Mexico, Australia and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements set out in this news release relating to the continued distribution and acceptance of Avivagen’s technology, anticipated growth in demand for Avivagen’s products, the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded and the size of market opportunities are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, these initial orders may not result in new orders for Avivagen’s products, demand for Avivagen’s products may not continue to grow and could decline, Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics in livestock feeds, new market access may not occur in the timeline or manner expected by Avivagen and the market opportunities may not be as large as Avivagen anticipates due to many factors, many of which are outside of Avivagen’s control. Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen’s most recent management’s discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright © 2020 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.

ⁱhttps://www.alltech.com/feed-survey-interactive-map

View source version on businesswire.com: https://www.businesswire.com/news/home/20200325005034/en/